© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Expert panelists center discussion around two patient cases to review use of newer anti-androgen deprivation therapy in the management of prostate cancer.
April 6th 2022
A comprehensive overview on androgen-deprivation therapy in prostate cancer and the various therapeutic agents it consists of.
Expert perspectives on the use of LHRH agonists versus antagonists in the management of prostate cancer.
April 13th 2022
Centering the discussion around a patient with nonmetastatic castration-resistant prostate cancer, experts share insight on optimal work-up and testing.
Shared insight on the selection of specific androgen receptor inhibitors for patients with nonmetastatic castration-resistant prostate cancer.
April 20th 2022
A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.
Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.
April 27th 2022
Discussion on the selection of therapy for a patient with metastatic HSPC in the context of available agents and FDA approvals.
Expert perspectives on optimal genomic testing practices in patients with prostate cancer.
May 4th 2022
Looking toward the future management of metastatic HSPC, experts consider the results of triplet combination trials like ARASENS and PEACE-1.